Subtype
Urinary System Carcinoma
CI-CAN-00004182Explore in graph →
670 active trials25 approved drugs87 evidence items
- NCIt
- C181197
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004182Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (391)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01149174 | Preoperative Intravesical Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer(EMDA/PRE-TUR) | completed | Phase 3 | 352 | University of Rome Tor VergataOTHER | 1 | Oct 4, 2011 | clinicaltrials |
| NCT00267748 | Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC) | completed | Phase 2 | 317 | PfizerINDUSTRY | 1 | Sep 5, 2011 |
| clinicaltrials |
| NCT00113529 | Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 42 | PfizerINDUSTRY | 1 | Aug 29, 2011 | clinicaltrials |
| NCT00478114 | Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC) | completed | Phase 3 | 15 | Mahidol UniversityOTHER | 1 | Aug 29, 2011 | clinicaltrials |
| NCT00444314 | Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 82 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Aug 4, 2011 | clinicaltrials |
| NCT01328691 | Prognostic Factor for Renal Cell Carcinoma (RCC) With Venous Tumor Thrombus | completed | — | 118 | Seoul National University HospitalOTHER | 1 | May 10, 2011 | clinicaltrials |
| NCT00330707 | Combined Use of BCG and Interferon Alpha in Bladder Cancer | completed | Phase 2 / Phase 3 | 140 | National University Hospital, SingaporeOTHER | 1 | Mar 4, 2011 | clinicaltrials |
| NCT00661609 | A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer | completed | Phase 2 | 54 | AstraZenecaINDUSTRY | 5 | Jan 12, 2011 | clinicaltrials |
| NCT01254838 | Novel Peptide Vaccination for Patients With Advanced Renal Cell Carcinoma | completed | Phase 1 | — | Iwate Medical UniversityOTHER | 0 | Dec 7, 2010 | clinicaltrials |
| NCT00460798 | SUTENT® In The First Line Treatment Of Renal Cell Carcinoma(SUNIKA) | completed | — | 356 | PfizerINDUSTRY | 0 | Nov 16, 2010 | clinicaltrials |
| NCT00509704 | Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma | completed | — | 10 | Radboud University Medical CenterOTHER | 1 | Nov 9, 2010 | clinicaltrials |
| NCT00077974 | A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma. | completed | Phase 2 | 106 | PfizerINDUSTRY | 1 | Oct 13, 2010 | clinicaltrials |
| NCT00895674 | Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar | completed | — | 2,840 | BayerINDUSTRY | 18 | Sep 30, 2010 | clinicaltrials |
| NCT01176552 | Granulocyte-macrophage Colony-stimulating Factor, Interferon and Interleukin-2 as Adjuvant Treatment for Renal Cancer | completed | Phase 2 | 35 | Kidney Cancer Research BureauOTHER | 1 | Aug 24, 2010 | clinicaltrials |
| NCT01182142 | Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients | completed | Phase 2 | 51 | Kidney Cancer Research BureauOTHER | 1 | Aug 24, 2010 | clinicaltrials |
| NCT00848640 | Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma(MERITS) | completed | Phase 2 | 75 | Egyptian Foundation For Cancer ResearchOTHER | 1 | May 26, 2010 | clinicaltrials |
| NCT00717743 | T Regulatory Cells in Renal Cell Carcinoma (PILOT STUDY) | completed | — | — | National University Hospital, SingaporeOTHER | 1 | Apr 9, 2010 | clinicaltrials |
| NCT00979381 | Study of the Immunoresponse in Patients Treated With a Tyrosine Kinase Inhibitor | completed | — | 75 | Radboud University Medical CenterOTHER | 1 | Mar 18, 2010 | clinicaltrials |
| NCT00884520 | An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037(VM4-037) | completed | Early Phase 1 | 16 | Siemens Molecular ImagingINDUSTRY | 1 | Mar 16, 2010 | clinicaltrials |
| NCT01087060 | Detection of Renal Malignancy of Complicated Renal Cysts | completed | — | 269 | Seoul National University HospitalOTHER | 1 | Mar 15, 2010 | clinicaltrials |
| NCT00422344 | A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma | completed | Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 26, 2010 | clinicaltrials |
| NCT00254540 | Study of SU011248 in Patients With Advanced Kidney Cancer | completed | Phase 2 | 51 | PfizerINDUSTRY | 1 | Feb 23, 2010 | clinicaltrials |
| NCT00782587 | Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer(IPOP) | completed | Phase 1 | 14 | Halozyme TherapeuticsINDUSTRY | 1 | Feb 8, 2010 | clinicaltrials |
| NCT00083889 | SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma | completed | Phase 3 | 750 | PfizerINDUSTRY | 11 | Jan 26, 2010 | clinicaltrials |
| NCT00089648 | SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma | completed | Phase 2 | 61 | PfizerINDUSTRY | 1 | Jan 12, 2010 | clinicaltrials |
| NCT00315237 | Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract | completed | Phase 3 | 364 | Pierre Fabre MedicamentINDUSTRY | 1 | Jan 7, 2010 | clinicaltrials |
| NCT00351949 | IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC) | completed | Phase 1 | 24 | Immutep S.A.S.INDUSTRY | 1 | Jan 7, 2010 | clinicaltrials |
| NCT00625768 | Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma | completed | Phase 1 | 13 | Antisoma ResearchINDUSTRY | 2 | Aug 25, 2009 | clinicaltrials |
| NCT00389285 | Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 52 | ZymoGeneticsINDUSTRY | 1 | May 27, 2009 | clinicaltrials |
| NCT00591188 | Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens | completed | Phase 2 | 49 | Kidney Cancer Research BureauOTHER | 1 | May 1, 2009 | clinicaltrials |
| NCT00043368 | PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) | completed | Phase 2 | 31 | PfizerINDUSTRY | 2 | Mar 12, 2009 | clinicaltrials |
| NCT00095108 | Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer | completed | Phase 1 | 43 | ZymoGeneticsINDUSTRY | 1 | Mar 9, 2009 | clinicaltrials |
| NCT00609401 | Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)(ROSORC) | completed | Phase 2 | 90 | Italian Trial in Medical OncologyOTHER | 1 | Feb 26, 2009 | clinicaltrials |
| NCT00043407 | CPG 7909 in Patients Wih Stage IV Renal Cell Cancer | completed | Phase 1 / Phase 2 | 42 | PfizerINDUSTRY | 0 | Feb 12, 2009 | clinicaltrials |
| NCT00216801 | Relationship of Ochratoxin A to Upper Urologic Cancers | completed | — | 60 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Jan 21, 2009 | clinicaltrials |
| NCT00496301 | Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCC(SOGUG-02-06) | completed | Phase 2 | 40 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Jan 14, 2009 | clinicaltrials |
| NCT00421512 | A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients | completed | Phase 1 | 28 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 11, 2008 | clinicaltrials |
| NCT00425204 | Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment | completed | Phase 2 | 31 | AmgenINDUSTRY | 0 | Sep 15, 2008 | clinicaltrials |
| NCT00422786 | Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma | completed | Phase 2 | 10 | Thallion PharmaceuticalsINDUSTRY | 1 | Jul 15, 2008 | clinicaltrials |
| NCT00095186 | Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma | completed | Phase 2 | 40 | AgennixINDUSTRY | 1 | Apr 10, 2008 | clinicaltrials |
| NCT00059735 | A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma | completed | Phase 2 | 30 | Eisai Inc.INDUSTRY | 2 | Mar 5, 2008 | clinicaltrials |
| NCT00001383 | A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833 | completed | Phase 1 | 52 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001683 | A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00056173 | Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 43 | Aptose Biosciences Inc.INDUSTRY | 1 | Jan 7, 2008 | clinicaltrials |
| NCT00073112 | A Study of ABT-751 in Patients With Renal Cell Cancer | completed | Phase 2 | 60 | AbbottINDUSTRY | 2 | Nov 29, 2007 | clinicaltrials |
| NCT00073125 | Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma | completed | Phase 2 | 103 | AbbottINDUSTRY | 2 | Aug 15, 2007 | clinicaltrials |
| NCT00192049 | A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer | completed | Phase 2 | 90 | Eli Lilly and CompanyINDUSTRY | 1 | May 17, 2007 | clinicaltrials |
| NCT00134186 | Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer | completed | Phase 2 | 43 | Pharmacyclics LLC.INDUSTRY | 1 | Mar 5, 2007 | clinicaltrials |
| NCT00191711 | Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk. | completed | Phase 2 | 43 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 26, 2007 | clinicaltrials |
| NCT00291369 | Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis | completed | Phase 3 | 456 | Centre Leon BerardOTHER | 1 | Feb 16, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Oct 4, 2011source: clinicaltrials